Peramivir Dosage
Medically reviewed by Drugs.com. Last updated on May 20, 2021.
Applies to the following strengths: 10 mg/mL
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Influenza
600 mg IV once as a single dose
Use: For the treatment of acute uncomplicated influenza in patients symptomatic no more than 2 days
Usual Pediatric Dose for Influenza
6 months to 12 years: 12 mg/kg IV once as a single dose
-Maximum dose: 600 mg/dose
13 years or older: 600 mg IV once as a single dose
Use: For the treatment of acute uncomplicated influenza in patients symptomatic no more than 2 days
Renal Dose Adjustments
Adults and adolescents 13 years or older:
-CrCl at least 50 mL/min: No adjustment recommended.
-CrCl 30 to 49 mL/min: 200 mg IV once
-CrCl 10 to 29 mL/min: 100 mg IV once
Pediatric patients 2 to 12 years of age:
-CrCl at least 50 mL/min: No adjustment recommended.
-CrCl 30 to 49 mL/min: 4 mg/kg IV once
---Maximum dose: 200 mg/dose
-CrCl 10 to 29 mL/min: 2 mg/kg IV once
---Maximum dose: 100 mg/dose
Pediatric patients 6 months to less than 2 years of age:
-CrCl less than 50 mL/min: Data not available
Comments:
-CrCl calculated using the Cockcroft-Gault formula.
-The pharmacokinetics (PKs) of this drug have not been studied in pediatric subjects with renal dysfunction; since the PKs in pediatric subjects with normal renal function are comparable to those in adults, the same proportional dose reduction is recommended in pediatric patients at least 2 years of age with renal dysfunction.
-Due to developmental immaturity of renal function in patients younger than 2 years, a recommendation for dose reduction cannot be made for patients 6 months to less than 2 years of age with CrCl less than 50 mL/min.
Liver Dose Adjustments
Data not available
Precautions
CONTRAINDICATIONS:
Known serious hypersensitivity or anaphylaxis to the active component or any of the ingredients
Safety and efficacy have not been established in patients younger than 6 months.
Consult WARNINGS section for additional precautions.
Dialysis
Hemodialysis: Dose should be adjusted based on renal function and administered after dialysis.
Other Comments
Administration advice:
-Administer within 2 days of onset of influenza symptoms.
-Administer via IV infusion for 15 to 30 minutes.
-If diluted solution is refrigerated, allow it to reach room temperature then administer immediately; discard unused diluted solution after 24 hours.
Storage requirements:
-Vials: Store in original containers at 20C to 25C (68F to 77F); excursions permitted to 15C to 30C (59F to 86F).
-Diluted solution: If not administered immediately, store refrigerated (2C to 8C [36F to 46F]) for up to 24 hours.
Reconstitution/preparation techniques:
-This drug must be diluted before infusion; the final concentration of diluted solution for administration should be between 1 and 6 mg/mL.
-Maximum infusion volume:
---Age 6 months to 1 year: 25 mL
---Age 1 year and older, weight 5 to less than 10 kg: 25 mL
---Age 1 year and older, weight 10 to less than 15 kg: 50 mL
---Age 1 year and older, weight 15 to less than 20 kg: 75 mL
---Age 1 year and older, weight at least 20 kg: 100 mL
-The manufacturer product information should be consulted.
IV compatibility:
-Compatible: 0.9% or 0.45% sodium chloride, 5% dextrose, lactated Ringers; materials commonly used for administration (e.g., polyvinylchloride [PVC] bags, PVC-free bags, polypropylene syringes, polyethylene tubing)
-Do not mix or co-infuse with other IV agents.
General (limitations of use):
-Efficacy based on clinical trials of naturally-occurring influenza in which the infections were mostly due to influenza A virus; limited number enrolled who were infected with influenza B virus.
-As influenza viruses change over time, resistant or more virulent mutations may emerge and decrease the efficacy of antiviral drugs; available information on influenza drug susceptibility patterns and treatment effects should be considered when deciding whether to use this drug.
-Efficacy not established in patients with serious influenza requiring hospitalization.
Monitoring:
-Psychiatric: For signs of abnormal behavior in patients with influenza
Patient advice:
-Seek medical attention at once if an allergic-like reaction occurs/is suspected.
-After receiving this drug, contact physician if signs of abnormal behavior occur.
More about peramivir
- Side effects
- Drug interactions
- During pregnancy or Breastfeeding
- En español
- Drug class: neuraminidase inhibitors
Patient resources
- Other brands
- Rapivab
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.